Evidence map›Paper›PMID 29296900›Full record

ArticleBlood advances2017

DNA and factor VII-activating protease protect against the cytotoxicity of histones.

Gerben Marsman, Helen von Richthofen, Ingrid Bulder, Florea Lupu, Jan Hazelzet, Brenda M Luken, Sacha Zeerleder

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 38 citations in OpenAlex.

  1. Regulation of histones in thromboinflammation.Frontiers in immunology · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Frontiers in immunology · 2022
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Gerben MarsmanDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Helen von RichthofenDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Ingrid BulderDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Florea LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.
Jan HazelzetDepartment of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; and.
Brenda M LukenDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Sacha ZeerlederDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Academic Medical Center · NLSanquin · NLErasmus MC · NLOklahoma Medical Research Foundation · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2M
Complement inhibition as sepsis therapyR01GM097747 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI LAMBRIS, JOHN D, LUPU, FLOREA · 2011 to 2014
$2.1M
FXI and SepsisR01GM116184 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2015 to 2018
$1.9M
Coagulation and Complement Activation in SepsisR01GM121601 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI LUPU, FLOREA · 2017 to 2020
$1.6M
Development of a mouse model of peptidoglycan-induced pathologyR21AI113020 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK, LUPU, FLOREA · 2014 to 2015
$471k
NIAID NIH HHS R21 AI113020NIAID NIH HHS U19 AI062629NIGMS NIH HHS R01 GM097747NIGMS NIH HHS R01 GM116184NIGMS NIH HHS R01 GM121601
6 · The paper itself

Abstract

Circulating histones have been implicated as major mediators of inflammatory disease because of their strong cytotoxic effects. Histones form the protein core of nucleosomes; however, it is unclear whether histones and nucleosomes are equally cytotoxic. Several plasma proteins that neutralize histones are present in plasma. Importantly, factor VII-activating protease (FSAP) is activated upon contact with histones and subsequently proteolyzes histones. We aimed to determine the effect of FSAP on the cytotoxicity of both histones and nucleosomes. Indeed, FSAP protected against histone-induced cytotoxicity of cultured cells in vitro. Upon incubation of serum with histones, endogenous FSAP was activated and degraded histones, which also prevented cytotoxicity. Notably, histones as part of nucleosome complexes were not cytotoxic, whereas DNA digestion restored cytotoxicity. Histones in nucleosomes were inefficiently cleaved by FSAP, which resulted in limited cleavage of histone H3 and removal of the N-terminal tail. The specific isolation of either circulating nucleosomes or free histones from sera of

Identifiers

PMID29296900
PMCPMC5728637
OpenAlexW2775692619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.